HC Wainwright rose to US$28.00 from Investing.com

Wainwright stopped trading for Lumos Pharma (NASDAQ:LUMO) and won the price of US$28.00. For the coming quarters of 2024, a business forecast of US$0.5 million and EPS of -US$0.93 are forecast. In 2024, an amount of US$2.1 million was earned.

The firm changed its EPS forecast for 2024 sales to -US$4.13 from -US$2.53 after an adjustment. This anpassung was sent after the message from Lumos Pharma on 30.06.2024 about Barmittel and an equivalent amount of 16.8 million US dollars for paints. After the second phase of financing is completed, the bet will be ready to fund in the first quarter of 2025.

Lumos Pharma has played an important role as Lumos capital is undergoing a phase 3 trial for the Wirkstoff candidates LUM-201. It is important to consider strategic options, a shareholder value column and the development of LUM-201. The best price-quality ratio and the rates of 28 US dollar mirrors become a more positive effect on the onternehmensaussichten wider.

In others, there are activities that put Lumos Pharma das Interest of Investors at ease. The Unternehmen have developed a Kaufempfehlung from EF Hutton, based on a Bewertung potential in more indications. The company set a rate of US$16.00 for the Lumos Pharma party, which was about the Wachstum saucesichten of the wider mirror of the world.

This approach is based on an analysis of financial models using the Free Cash Flow to the Firm (FCFF), the Deconfigured EPS (dEPS) and the Sum-of-the-Parts (SOP) model. EF Hutton had the opportunity to benefit from the forecast of the Aktienanzahl organization together with the capital with Lumos Pharma.

Gleichzeitig hat Lumos Pharma Updates on the phase 3 study conducted for LUM-201, an oral therapy candidate for treatment of moderate pathologies for hormonal treatment. The study starting in the quarter of 2025, with a estimated budget of 85 and 100 million US dollars. It reports a solid financial position with 16.8 million US dollars in Barmitteln, Barmittel equivalents and kurzfristigen Investments.

Lumos Pharma has developed a strategic strategy with Piper Sandler and has attracted global interest. The third part of the company has established a strategic partner organization and can thus also generate financial financing.

InvestingPro Acknowledgment

Aktuelle InvestingPro-Daten are based on the analysis of HC Wainwright at Lumos Pharma (NASDAQ:LUMO). The market capitalization of the Unternehmens had a value of 32.01 million US dollars and was an active market practice with a broader mirror. Trotz of the prospects for the EPS forecast for the company years 2024 during the firm that InvestingPro-Tipps had, while Barmittel stopped as debt abroad, was with the messages of the American works council and the financial outlook, the bet was in the first quarter of 2025 ready for financing honor , überinstimmt.

The InvestingPro data has shown a 33.27% return in the last month of the month, amounting to US$1.49 million. This trend is based on the analysis of analysts conducting a year-long study of InvestingPro tips. The negative bet of -37.62 million US dollars and the profitability in the last month of the US economy, when Lumos gegenübersteht, was a similar capital investment for the Phase-3 Study of the LUM-201 erclaren.

On the positive side, the brands have a strong Kursentwicklung effect, with a return of 69.83% in the third month of the month and a lead of 39.72% in the last month of the month. This dynamic course can support market optimism in the strategic options of the internal systems and the capabilities of the LUM-201 wider mirror.

For investors, who perform some analysis, InvestingPro offers 7 other tips for Lumos Pharma, which generate part of the financial prosperity and market position of our external companies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.